Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14248952 | 0.81 | CYP1A2 (0.39) | RAB9AGAAACHEALDH1A1 | |
| SCHEMBL14248892 | 0.73 | BUB1 (0.33) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27083287 | 0.68 | SIGMAR1 (0.34) | SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27082620 | 0.68 | SIGMAR1 (0.34) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL24925405 | 0.67 | IDO1 (0.33) | RAB9ASMN1; SMN2 | |
| SCHEMBL18338406 | 0.67 | SMN1; SMN2 (0.34) | RAB9ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL12391314 | 0.65 | HTR2A (0.35) | SMN1; SMN2 | |
| SCHEMBL26924013 | 0.60 | ALOX5 (0.39) | ALOX5ALDH1A1 | |
| SCHEMBL11916069 | 0.60 | ACHE (0.37) | RAB9ASMN1; SMN2GAAACHEALDH1A1 | |
| SCHEMBL26650844 | 0.60 | TDP2 (0.33) | GAAACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2012172093-A1 | DIHYDROINDOLIZINE DERIVATE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-12-20 | — | — | WO | disclosed |